1 / 17

Nucleic Acid Therapeutics CDMO Market

The global nucleic acid therapeutics CDMO market is expected to reach $4,463.7 Million by 2030, with a CAGR of 11.09 % during the forecast period 2021-2030.<br>

bisreports
Download Presentation

Nucleic Acid Therapeutics CDMO Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis Table of Content Attribution: https://pixabay.com/photos/tire-rim-car-mechanic-114259/ Nucleic Acid Therapeutics CDMO Market Focus on Product, Technology, and End User Analysis and Forecast: 2021-2030 September 2021 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Nucleic Acid Therapeutics CDMO Market Copyright © 2021 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary ........................................................................ 18 Research Methodology ................................................................... 24 1.Markets .................................................................................... 29 1.1 Industry Outlook .............................................................................................. 30 1.1.1Global Nucleic Acid Therapeutics CDMO Market Overview .................... 30 1.2 Product Definition ............................................................................................ 30 1.3 Global Nucleic Acid Therapeutics CDMO Market Footprint, ($ Million), 2020-2030.......................................................................................................... 30 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape ................................ 32 1.5 Significant Usage of Nucleic Acid in Therapeutics ...................................... 33 1.6 Types of Nucleic Acid Synthesized for Therapeutics ................................... 34 1.6.1Anti‐ ‐Sense Oligonucleotides (ASOs) and DNA Aptamers ....................... 34 1.6.2RNA interference [RNAi] and short interfering RNAs [siRNAs] .............. 34 1.6.3MicroRNAs ................................................................................................... 34 1.6.4RNA Aptamers and RNA Decoys ............................................................... 35 1.6.5Ribozymes ................................................................................................... 35 1.6.6Circular RNAs .............................................................................................. 35 1.7 Market Dynamics ............................................................................................. 35 1.7.1Market Drivers ............................................................................................. 36 Nucleic Acid Therapeutics CDMO Market 1.7.1.1 Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products ................................................. 36 1.7.1.2 Reduction in Overall Manufacturing Cost at CDMOs ........................................ 37 1.7.1.3 Rising Approvals of Nucleic Acid Therapeutics................................................. 38 1.7.2Restraints ..................................................................................................... 40 1.7.2.1 Lack of Expertise in Nucleic Acid Manufacturing .............................................. 40 1.7.2.2 Supply Chain and Logistical Challenges........................................................... 40 3 All rights reserved at BIS Research Inc.

  4. 1.7.2.3 Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids ......... 41 1.7.3Opportunities ............................................................................................... 41 1.7.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies .................. 41 1.7.3.2 Accelerating Research and Development Along with Technology .................... 42 1.7.3.3 Growth in Developing Countries ....................................................................... 42 2.Competitive Landscape ............................................................ 43 2.1 New Offerings and Funding and Investments ............................................... 44 2.2 Regulatory and Legal ...................................................................................... 44 2.3 Mergers and Acquisitions ............................................................................... 44 2.4 Synergistic Activities ...................................................................................... 45 2.5 Market Share Analysis .................................................................................... 45 2.6 Growth Share Analysis.................................................................................... 46 3. Chemical Synthesis Method ..................................................... 49 3.1 Overview ........................................................................................................... 50 3.1.1Solid-Phase Oligonucleotide Synthesis .................................................... 51 3.1.1.1 Advantages and Challenges of SPOS .............................................................. 51 3.1.1.2 Method ............................................................................................................. 52 3.1.1.2.1Deprotecting/Detritylation ......................................................................................... 52 3.1.1.2.2Coupling ................................................................................................................... 52 3.1.1.2.3Oxidation/Sulfurization ............................................................................................. 52 3.1.1.2.4Capping .................................................................................................................... 53 Nucleic Acid Therapeutics CDMO Market 3.1.1.3 Cleavage and Deprotection .............................................................................. 53 3.1.1.4 Purification ....................................................................................................... 53 3.1.2Liquid-Phase Oligonucleotide Synthesis .................................................. 53 3.1.2.1 Advantages and Challenges of LPOS .............................................................. 53 4. Technology .............................................................................. 55 4.1 Overview ........................................................................................................... 56 4.1.1Column-Based Method ............................................................................... 56 4 All rights reserved at BIS Research Inc.

  5. 4.1.2Microarray-Based Method .......................................................................... 57 5. End-User ................................................................................. 59 5.1 Overview ........................................................................................................... 60 5.1.1Pharmaceutical Companies ........................................................................ 60 5.1.2Academic Research Institute ..................................................................... 61 5.1.3Diagnostic Laboratories ............................................................................. 62 6.Products .................................................................................. 64 6.1 Global Nucleic Acid Therapeutics CDMO Market (by Product) ................... 65 6.1.1Standard Nucleic Acid ................................................................................ 66 6.1.2Micro-Scale Nucleic Acid ............................................................................ 68 6.1.3Large-Scale Nucleic Acid ............................................................................ 69 6.1.4Custom Nucleic Acid ................................................................................... 70 6.1.5Modified Nucleic Acid ................................................................................. 71 6.1.6Primers ......................................................................................................... 72 6.1.7Probes .......................................................................................................... 73 6.1.8Other Nucleic Acid ...................................................................................... 74 6.1.9Other Services ............................................................................................. 75 7. Regions ................................................................................... 77 7.1 Overview ........................................................................................................... 78 7.2 North America .................................................................................................. 80 Nucleic Acid Therapeutics CDMO Market 7.2.1U.S. ............................................................................................................... 82 7.2.2Canada ......................................................................................................... 83 7.3 Europe .............................................................................................................. 85 7.3.1Germany ....................................................................................................... 86 7.3.2U.K. ............................................................................................................... 87 7.3.3France ........................................................................................................... 88 7.3.4Italy ............................................................................................................... 89 5 All rights reserved at BIS Research Inc.

  6. 7.3.5Spain ............................................................................................................. 90 7.3.6Rest-of-Europe............................................................................................. 91 7.4 Asia-Pacific ...................................................................................................... 93 7.4.1China ............................................................................................................ 94 7.4.2India .............................................................................................................. 95 7.4.3Japan ............................................................................................................ 96 7.4.4Australia ....................................................................................................... 97 7.4.5Rest-of-Asia-Pacific ..................................................................................... 98 7.5 Rest-of-the-World ............................................................................................ 99 8. Markets - Competitive Benchmarking & Company Profiles ...... 100 8.1 Company Profile ............................................................................................ 101 8.2 Agilent Technologies, Inc. ............................................................................ 102 8.2.1Company Overview ................................................................................... 102 8.2.2Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 102 8.2.3Financials ................................................................................................... 104 8.2.4Key Insights About Financial Health of the Company ........................... 107 8.2.5SWOT Analysis .......................................................................................... 108 8.3 Ajinomoto Co. Inc. ......................................................................................... 109 8.3.1Company Overview ................................................................................... 109 Nucleic Acid Therapeutics CDMO Market 8.3.2Role of Ajinomoto Co. Inc. in Global Nucleic Acid Therapeutics CDMO Market ............................................................................................. 109 8.3.3Financials ................................................................................................... 110 8.3.4SWOT Analysis .......................................................................................... 112 8.4 Bachem Holding AG. ..................................................................................... 113 8.4.1Company Overview ................................................................................... 113 6 All rights reserved at BIS Research Inc.

  7. 8.4.2Role of Bachem Holding AG. in Global Nucleic Acid Therapeutics CDMO Market ............................................................................................. 113 8.4.3SWOT Analysis .......................................................................................... 114 8.5 Biospring GmbH ............................................................................................ 115 8.5.1Company Overview ................................................................................... 115 8.5.2Role of Biospring GmbH in Global Nucleic Acid Therapeutics CDMO Market ......................................................................................................... 115 8.5.3SWOT Analysis .......................................................................................... 116 8.6 Corden Pharma International ........................................................................ 117 8.6.1Company Overview ................................................................................... 117 8.6.2Role of Corden Pharma International in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 117 8.6.3SWOT Analysis .......................................................................................... 119 8.7 Danaher Corporation ..................................................................................... 120 8.7.1Company Overview ................................................................................... 120 8.7.2Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 120 8.7.3Financials ................................................................................................... 121 8.7.4Key Insights About Financial Health of the Company ........................... 124 8.7.5SWOT Analysis .......................................................................................... 125 8.8 Guangzhou Ruibo Biotechnology Co., Ltd. ................................................. 126 Nucleic Acid Therapeutics CDMO Market 8.8.1Company Overview ................................................................................... 126 8.8.2Role of Guangzhou Ruibo Biotechnology Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market ............................................... 126 8.8.3SWOT Analysis .......................................................................................... 128 8.9 KNC Laboratories Co., Ltd. ........................................................................... 129 8.9.1Company Overview ................................................................................... 129 7 All rights reserved at BIS Research Inc.

  8. 8.9.2Role of KNC Laboratories Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 129 8.9.3Financials ................................................................................................... 130 8.9.4SWOT Analysis .......................................................................................... 131 8.10LGC Limited ................................................................................................... 132 8.10.1Company Overview ................................................................................... 132 8.10.2Role of LGC Limited in the Global Nucleic Acid Therapeutics CDMO Market ......................................................................................................... 132 8.10.3Financials ................................................................................................... 133 8.10.4Key Insights About Financial Health of the Company ........................... 134 8.10.5SWOT Analysis .......................................................................................... 135 8.11Merck KGaA ................................................................................................... 136 8.11.1Company Overview ................................................................................... 136 8.11.2Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market ......................................................................................................... 136 8.11.3Financials ................................................................................................... 137 8.11.4Key Insights About Financial Health of the Company ........................... 140 8.11.5SWOT Analysis .......................................................................................... 141 8.12Nippon Shokubai Co., Ltd. ............................................................................ 142 8.12.1Company Overview ................................................................................... 142 8.12.2Role of Nippon Shokubai Co., Ltd. in the Global Nucleic Acid Nucleic Acid Therapeutics CDMO Market Therapeutics CDMO Market ...................................................................... 142 8.12.3Financials ................................................................................................... 143 8.12.4Key Insights About Financial Health of the Company ........................... 144 8.12.5SWOT Analysis .......................................................................................... 145 8.13Nitto Denko Avecia Inc. ................................................................................. 146 8.13.1Company Overview ................................................................................... 146 8 All rights reserved at BIS Research Inc.

  9. 8.13.2Role of Nitto Denko Avecia Inc. in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 146 8.13.3SWOT Analysis .......................................................................................... 148 8.14QIAGEN N.V. ................................................................................................... 149 8.14.1Company Overview ................................................................................... 149 8.14.2Role of QIAGEN N.V. in the Global Nucleic Acid Therapeutics CDMO Market ......................................................................................................... 149 8.14.3Financials ................................................................................................... 150 8.14.4Key Insights About Financial Health of the Company ........................... 152 8.14.5SWOT Analysis .......................................................................................... 153 8.15ST Pharm Co Ltd ............................................................................................ 154 8.15.1Company Overview ................................................................................... 154 8.15.2Role of ST Pharm Co Ltd in Global Nucleic Acid Therapeutics CDMO Market ............................................................................................. 154 8.16Sumitomo Chemical Co., Ltd. ....................................................................... 156 8.16.1Company Overview ................................................................................... 156 8.16.2Role of Sumitomo Chemical Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 156 8.16.3Financials ................................................................................................... 158 8.16.4Key Insights About Financial Health of the Company ........................... 160 8.16.5SWOT Analysis .......................................................................................... 161 Nucleic Acid Therapeutics CDMO Market 8.17Syngene International Limited ...................................................................... 162 8.17.1Company Overview ................................................................................... 162 8.17.2Role of Syngene International Limited in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 162 8.17.3Financials ................................................................................................... 163 8.17.4Key Insights About Financial Health of the Company ........................... 164 8.17.5SWOT Analysis .......................................................................................... 165 9 All rights reserved at BIS Research Inc.

  10. 8.18Thermo Fisher Scientific Inc. ........................................................................ 166 8.18.1Company Overview ................................................................................... 166 8.18.2Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 166 8.18.3Financials ................................................................................................... 167 8.18.4Key Insights About Financial Health of the Company ........................... 169 8.18.5SWOT Analysis .......................................................................................... 170 8.19Wuxi AppTec .................................................................................................. 171 8.19.1Company Overview ................................................................................... 171 8.19.2Role of Wuxi AppTec in the Global Nucleic Acid Therapeutics CDMO Market ............................................................................................. 171 8.19.3Financials ................................................................................................... 172 8.19.4Key Insights About Financial Health of the Company ........................... 174 8.19.5SWOT Analysis .......................................................................................... 175 8.20Yamasa Corporation ...................................................................................... 176 8.20.1Company Overview ................................................................................... 176 8.20.2Role of Yamasa Corporation in the Global Nucleic Acid Therapeutics CDMO Market ...................................................................... 176 8.20.3SWOT Analysis .......................................................................................... 178 Nucleic Acid Therapeutics CDMO Market 10 All rights reserved at BIS Research Inc.

  11. List of Figures Figure 1:Global Nucleic Acid Therapeutics CDMO Market, Realistic and Optimistic Scenario, $Million Figure 2:Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics Figure 3:Share of Key Market Strategies and Developments, July 2017-July 2021 Figure 4:Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company), 2019-2020 Figure 5:Global Nucleic Acid Therapeutics CDMO Market Research Methodology Figure 6:Primary Research Methodology Figure 7:Global Nucleic Acid Therapeutics CDMO Market, $Million, 2020-2030 Figure 8:Optimistic View of Global Nucleic Acid Therapeutics CDMO Market, $Million Figure 9:Overview of CRO and CDMO Services Figure 10:Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics Figure 11:Deal Value of Mergers and Acquisitions Involving Cell and Gene Therapies (2016-2019) Figure 12:Share of Key Market Strategies and Developments, July 2017-July 2021 Figure 13:Share of Mergers and Acquisitions (by Company), 2017-2021 Figure 14:Share of Synergistic Activities (by Company), 2017-2021 Figure 15:Market Share Analysis for Global Nucleic Acid Therapeutics CDMO Market, 2020 Figure 16:Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company),2019- 2020 Figure 17:Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method) Figure 18:Share of Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), 2020 and 2030 Figure 19:Solid-Phase Oligonucleotide Synthesis Market Size and Forecast Figure 20:Liquid-Phase Oligonucleotide Synthesis Market Size and Forecast Figure 21:Share of Global Nucleic Acid Therapeutics CDMO Market (by Technology), 2020 and 2030 Figure 22:Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), 2020-2030 Figure 23:Global Nucleic Acid Therapeutics CDMO Market (by Microarray-Based Method), 2020-2030 Figure 24:Global Nucleic Acid Therapeutics CDMO Market, by End User, 2020 and 2030 ($Million) Nucleic Acid Therapeutics CDMO Market Figure 25:Global Nucleic Acid Therapeutics CDMO Market, by Pharmaceutical and Biotechnology Companies Figure 26:Global Nucleic Acid Therapeutics CDMO Market, by Academic Research Institutes Figure 27:Global Nucleic Acid Therapeutics CDMO Market, by Diagnostic Laboratories Figure 28:Global Nucleic Acid Therapeutics CDMO Market (by Product) Figure 29:Share of Global Nucleic Acid Therapeutics CDMO Market (by Product), 2020 and 2030 ($Million) Figure 30:Global Nucleic Acid Therapeutics CDMO Market, by Standard Nucleic Acid Figure 31:Global Nucleic Acid Therapeutics CDMO Market, by Micro-Scale Nucleic Acid Figure 32:Global Nucleic Acid Therapeutics CDMO Market, by Large-Scale Nucleic Acid Market 11 All rights reserved at BIS Research Inc.

  12. Figure 33:Global Nucleic Acid Therapeutics CDMO Market, by Custom Nucleic Acid Figure 34:Global Nucleic Acid Therapeutics CDMO Market, by Modified Nucleic Acid Figure 35:Global Nucleic Acid Therapeutics CDMO Market Primer Market, by Primers Figure 36:Global Nucleic Acid Therapeutics CDMO Market, by Primer Figure 37:Global Nucleic Acid Therapeutics CDMO Market, by Others NA Figure 38:Global Nucleic Acid Therapeutics CDMO Market, Other Services Figure 39:Global Nucleic Acid Therapeutics CDMO Market (by Region), Million Units, 2020-2030 Figure 40:Share of North America Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million Figure 41:North America: Market Dynamics Figure 42:U.S. Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million Figure 43:Canada Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million Figure 44:Share of Europe Nucleic Acid Therapeutics CDMO Market (by Country), 2020-2030, $Million Figure 45:Europe: Market Dynamics Figure 46:Germany Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 47:U.K. Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 48:France Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 49:Italy Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 50:Spain Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 51:Rest-of-Europe Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 52:APAC: Market Dynamics Figure 53:Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million Figure 54:China Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 55:India Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 56:Japan Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 57:Australia Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 58:Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Nucleic Acid Therapeutics CDMO Market Figure 59:Rest-of-the-World Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million Figure 60:Shares of Key Company Profiles Figure 61:Agilent Technologies, Inc.: Product Portfolio Figure 62:Agilent Technologies, Inc.: Overall Financials, 2018-2020 Figure 63:Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020 Figure 64:Agilent Technologies, Inc.: Revenue (by Region), 2018-2020 Figure 65:Agilent Technologies, Inc.: R&D Expenditure, 2018-2020 Figure 66:Agilent Technologies, Inc.: SWOT Analysis Figure 67:Ajinomoto Co. Inc,: Overall Product Portfolio 12 All rights reserved at BIS Research Inc.

  13. Figure 68:Ajinomoto Co., Inc.: Overall Financials, 2017-2019 Figure 69:Ajinomoto Co., Inc.: Revenue (by Segment), 2017-2019 Figure 70:Ajinomoto Co., Inc.: SWOT Analysis Figure 71:Bachem Holding AG.: Overall Product Portfolio Figure 72:Bachem Holding AG.: SWOT Analysis Figure 73:Biospring GmbH: Overall Product Portfolio Figure 74:Biospring GmbH: SWOT Analysis Figure 75:Corden Pharma International: Overall Product Portfolio Figure 76:Corden Pharma International: SWOT Analysis Figure 77:Danaher Corporation: Product Portfolio Figure 78:Danaher Corporation: Overall Financials, 2018-2020 Figure 79:Danaher Corporation: Revenue (by Segment), 2018-2020 Figure 80:Danaher Corporation: Revenue (by Region), 2018-2020 Figure 81:Danaher Corporation: R&D Expenditure, 2018-2020 Figure 82:Danaher Corporation: SWOT Analysis Figure 83:Guangzhou Ruibo Biotechnology Co., Ltd.: Product Portfolio Figure 84:Guangzhou Ruibo Biotechnology Co., Ltd: SWOT Analysis Figure 85:KNC Laboratories Co., Ltd.: Overall Product Portfolio Figure 86:KNC Laboratories Co., Ltd.: Overall Financials, 2018-2020 Figure 87:KNC Laboratories Co., Ltd.: SWOT Analysis Figure 88:LGC Limited: Overall Product Portfolio Figure 89:LGC Limited: Overall Financials, 2018-2020 Figure 90:LGC Limited: Revenue (by Segment), 2018-2020 Figure 91:LGC Limited: R&D Expenditure, 2018-2020 Figure 92:LGC Limited: SWOT Analysis Figure 93:Merck KGaA: Product Portfolio Figure 94:Merck KGaA: Overall Financials, 2018-2020 Figure 95:Merck KGaA: Revenue (by Segment), 2018-2020 Nucleic Acid Therapeutics CDMO Market Figure 96:Merck KGaA: Revenue (by Region), 2018-2020 Figure 97:Merck KGaA: R&D Expenditure, 2018-2020 Figure 98:Merck KGaA: SWOT Analysis Figure 99:Nippon Shokubai Co., Ltd.: Overall Financials, 2018-2020 Figure 100:Nippon Shokubai Co., Ltd: Revenue (by Segment), 2018-2020 Figure 101:Nippon Shokubai Co., Ltd: R&D Expenditure, 2018-2020 Figure 102:Nippon Shokubai Co., Ltd: SWOT Analysis Figure 103:Nitto Denko Avecia Inc.: Product Portfolio Figure 104:Nitto Denko Avecia Inc.: SWOT Analysis Figure 105:QIAGEN N.V.: Product Portfolio Figure 106:QIAGEN N.V.: Overall Financials, 2018-2020 13 All rights reserved at BIS Research Inc.

  14. Figure 107:QIAGEN N.V.: Revenue (by Segment), 2018-2020 Figure 108:QIAGEN N.V.: Revenue (by Region), 2018-2020 Figure 109:QIAGEN N.V.: R&D Expenditure, 2018-2020 Figure 110:QIAGEN N.V.: SWOT Analysis Figure 111:ST Pharm Co Ltd : Overall Product Portfolio Figure 112:ST Pharm Co Ltd: SWOT Analysis Figure 113:Sumitomo Chemical Co., Ltd.: Overall Product Portfolio Figure 114:Sumitomo Chemical Co., Ltd: Overall Financials, 2018-2020 Figure 115:Sumitomo Chemical Co., Ltd.: Revenue (by Segment), 2018-2020 Figure 116:Sumitomo Chemical Co., Ltd: R&D Expenditure, 2018-2020 Figure 117:Sumitomo Chemical Co., Ltd.: SWOT Analysis Figure 118:Syngene International Limited: Overall Product Portfolio Figure 119:Syngene International Limited: Overall Financials, 2018-2020 Figure 120:Syngene International Limited: Revenue (by Region), 2018-2020 Figure 121:Syngene International Limited: R&D Expenditure, 2018-2020 Figure 122:Syngene International Limited: SWOT Analysis Figure 123:Thermo Fisher Scientific Inc.: Product Portfolio Figure 124:Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020 Figure 125:Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020 Figure 126:Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020 Figure 127:Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020 Figure 128:Thermo Fisher Scientific Inc.: SWOT Analysis Figure 129:Wuxi AppTec: Overall Product Portfolio Figure 130:Wuxi AppTec: Overall Financials, 2018-2020 Figure 131:Wuxi AppTec: Revenue (by Segment), 2018-2020 Figure 132:Wuxi AppTec: Revenue (by Region), 2018-2020 Figure 133:Wuxi AppTec: R&D Expenditure, 2018-2020 Figure 134:Wuxi AppTec: SWOT Analysis Nucleic Acid Therapeutics CDMO Market Figure 135:Yamasa Corporation: Overall Product Portfolio Figure 136:Yamasa Corporation: SWOT Analysis 14 All rights reserved at BIS Research Inc.

  15. List of Tables Table 1: Table 2: Oligonucleotide Therapies Approved by the FDA Nucleic Acid Therapies Approved by FDA and EMA Table 3: Table 4: Companies offering Standard Nucleic Acid Companies offering Micro-Scale Nucleic Acid Table 5: Table 6: Companies offering Large-Scale Nucleic Acid Companies offering Custom Nucleic Acid Table 7: Companies offering Modified Nucleic Acid Table 8: Table 9: Companies offering Primers Companies offering Probes Table 10:Companies offering Other NA Table 11:Companies offering Other Services Nucleic Acid Therapeutics CDMO Market 15 All rights reserved at BIS Research Inc.

  16. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Nucleic Acid Therapeutics CDMO Market 16 All rights reserved at BIS Research Inc.

  17. BIS RESEARCH INC. Nucleic Acid Therapeutics CDMO Market 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 17 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related